Thymosin Alpha-1 2026: Cost, Samples & Access for the Immunomodulatory Peptide
Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide naturally produced by the thymus. It has been studied for decades for its role in T-cell maturation and immune-system signaling. The peptide is approved as Zadaxin in over 30 countries (not the US) for use in chronic hepatitis B, hepatitis C, and as adjuvant therapy in certain cancer protocols.
In the US, thymosin alpha-1 is not FDA-approved as a standalone product. It is available via 503A compounding pharmacies on prescription. The molecule was placed on the FDA Cat-2 interim list in late 2023 but removed in September 2024 — current status is in regulatory limbo pending PCAC review.
Clinical use focuses on immune-support protocols, often in patients with chronic infection, immune dysregulation, or as part of broader hormone-optimization stacks where immune support is a goal.
- 10 programs ranked
- Editor-reviewed
- Reader-verified
- Updated weekly
What's actually available: Thymosin Alpha-1 samples in 2026
Three paths for people typing “thymosin alpha-1samples” — what they actually mean, typical cost, and who each path fits.
| Path | What it actually is | Typical cost | Best for |
|---|---|---|---|
| Specialty peptide clinic (Marek / Defy / LIVV) | Specialty clinic with full intake including immune-system labs and protocol design. | $199-449 / month | Patients with chronic infection, immune dysregulation, or running immune-focused protocols |
| Longevity telehealth (AgelessRx, etc.) | Telehealth offering thymosin alpha-1 in broader longevity or immune-support stacks. | $129-249 / month subscription | Patients integrating thymosin alpha-1 into broader peptide or longevity protocols |
| 503A pharmacy via clinician | Direct 503A fill via established clinician relationship. | $120-280 / vial | Patients with established prescription managing ongoing cost |
How Thymosin Alpha-1 samples actually work
What thymosin alpha-1 actually does
Thymosin alpha-1 modulates T-cell development and immune-cell signaling. The mechanism includes activation of toll-like receptors on dendritic cells, modulation of natural killer cell activity, and shifts in cytokine production patterns. The result is broad immune-system support rather than targeted immunosuppression or stimulation. This is why clinical use covers a range of immune-related indications rather than a single condition.
Why Zadaxin matters for the US picture
Most peptides in the US compounding directory have no FDA-approved counterpart anywhere. Thymosin alpha-1 is different — it has been used clinically as Zadaxin in over 30 countries for over two decades, primarily for chronic hepatitis. That international clinical use generates a substantial post-market safety record that informs US off-label use. The US regulatory gap reflects commercial economics and small-market dynamics, not novel safety concerns.
Where thymosin alpha-1 sits in clinical protocols
Specialty clinics use thymosin alpha-1 in patients with chronic infection (Lyme, EBV reactivation, chronic viral conditions), in patients with immune dysregulation, and as an adjunct in cancer-survivorship or post-chemotherapy protocols. Hormone-optimization clinics may include it in broader optimization stacks where immune support is a clinical goal.
Thymosin Alpha-1 is the rare peptide with substantial international clinical use behind it — Zadaxin has been approved in 30+ countries for over two decades. The US regulatory path is the gap; the clinical evidence is not.
Thymosin Alpha-1 cost in 2026: every legitimate price path
What you'll actually pay depends on insurance, the path you take, and whether you stay on the brand-name drug. Here's the real money:
| Path | First month | Ongoing | Notes |
|---|---|---|---|
| Specialty peptide clinic | $300-700 | $199-449 / mo | Includes consult + immune-system labs + protocol design. |
| Longevity telehealth subscription | $149-279 | $129-249 / mo | Often bundled with sermorelin or other peptides in broader stack. |
| 503A pharmacy via clinician | $240-560 | $120-280 / vial | Lowest ongoing cost with established prescription. |
What to expect on Thymosin Alpha-1: your first weeks
Baseline immune-system labs (CBC with differential, immunoglobulins, NK cell function if available) before initiating.
Subjective effects on energy, infection recurrence, or chronic-condition symptoms vary on a multi-week timeframe.
Lab response (where applicable) typically rechecked at 8-12 weeks.
Clinical evidence behind Thymosin Alpha-1
Thymosin alpha-1 has substantial international clinical evidence — primarily from the Zadaxin trials in chronic hepatitis B, C, and as adjuvant cancer therapy. US off-label use extrapolates from this evidence. Mechanism research is well-developed; outcome research outside the on-label hepatitis indication is more variable.
Thymosin Alpha-1side effects & who shouldn't take it
This is not medical advice. Discuss every medication decision with a licensed clinician who knows your full medical history.
Common side effects
- •Injection-site soreness or transient redness
- •Mild flushing post-injection (uncommon)
- •No significant systemic side-effect signal in published clinical use
- •Generally well tolerated relative to most peptides in the directory
Who shouldn't take Thymosin Alpha-1
- •Patients with active autoimmune disease (relative contraindication; modulation could affect disease activity)
- •Patients on immunosuppressive therapy for transplant or autoimmune disease
- •Pregnancy or breastfeeding
- •Patients with significant immune-system pathology requiring specialist management
Eligibility for Thymosin Alpha-1
- •Adult patients with immune-support indication or chronic infection adjunct therapy goal
- •No active autoimmune disease
- •Not currently on transplant-related immunosuppression
- •Willingness to maintain clinical follow-up
Thymosin Alpha-1 samples: frequently asked
Is thymosin alpha-1 the same as Zadaxin?
Yes — Zadaxin is the brand name of thymosin alpha-1 approved in 30+ countries (not the US). The molecule is the same. Most US clinical use is via 503A-compounded equivalent.
Why isn't thymosin alpha-1 FDA-approved in the US?
Commercial economics rather than safety concerns. SciClone (the developer) pursued FDA approval for hepatitis indications in the 2000s but did not complete the approval pathway. The molecule has substantial international clinical use; the US regulatory gap reflects market dynamics, not novel safety questions.
Can I use thymosin alpha-1 if I have an autoimmune condition?
Generally not without specialist oversight. Thymosin alpha-1 is an immunomodulator; in autoimmune conditions, immune modulation could affect disease activity in either direction. Patients with autoimmune conditions should only consider thymosin alpha-1 under specialist supervision.
How does thymosin alpha-1 compare to thymosin beta-4 (TB-500)?
Different molecules with different mechanisms. Thymosin alpha-1 is an immunomodulator targeting T-cell signaling. Thymosin beta-4 (TB-500) is an actin-sequestering peptide studied for tissue repair. The 'thymosin' shared name reflects original discovery in thymus tissue but the molecules act through different pathways.
Is thymosin alpha-1 still legal to prescribe in the US?
Yes. It was removed from the FDA Cat-2 list in September 2024 and is currently in regulatory limbo pending PCAC review. 503A compounding continues; clinical prescription remains routine. Status may change — we update this page when it does.